26 min listen
Treating genitourinary malignancies in the COVID-19 era
FromBlood & Cancer
ratings:
Length:
34 minutes
Released:
May 7, 2020
Format:
Podcast episode
Description
How should oncologists be treating genitourinary malignancies during the COVID-19 pandemic? Aly-Khan A. Lalani, MD, of McMaster University in Hamilton, Ontario, and colleagues recently published recommendations that help answer that question (Can Urol Assoc J. 2020 May;14[5]:e154-8). In this episode, Dr. Lalani reviews some of these recommendations with podcast host David H. Henry, MD, of Pennsylvania Hospital in Philadelphia. The pair discuss when and how to use androgen receptor axis-targeted therapies and radium-223 in metastatic prostate cancer, platinum-based chemotherapy in advanced urothelial carcinoma, and checkpoint inhibitors in patients with urothelial carcinoma or renal cell carcinoma. * * * Disclosures: Dr. Henry reported having no financial disclosures relevant to this episode. Dr. Lalani has relationships with Astellas Pharma, Bayer, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche/Genentech, TerSera, AbbVie, Eisai, Ipsen, and Janssen. * * * For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgehemonc David Henry on Twitter: @davidhenrymd Ilana Yurkiewicz on Twitter: @ilanayurkiewicz
Released:
May 7, 2020
Format:
Podcast episode
Titles in the series (100)
Sickle cell update: Treating pain and progress toward cure: When it comes to treating pain related to sickle cell disease, consider the underlying factors, from constipation to compression spine deformity. That’s just some of the advice from Ifeyinwa Osunkwo, MD, of Atrium Health and Levine Cancer Institute... by Blood & Cancer